Chemoinformatic analysis of biologically active macrocycles

Current Topics in Medicinal Chemistry

Volumn 10, Issue 14, 2010, Pages 1361-1379

  Brandt, Wolfgang ^a   Haupt, V Joachim ^a   Wessjohann, Ludger A ^a  

^a LEIBNIZ INSTITUTE OF PLANT BIOCHEMISTRY   (Germany)

Author keywords

Antibiotics; Anticancer agents; Chemoinformatics; Computational chemistry; Databases; Macrocycles; Natural products; Quantitative structure activity relationship (QSAR)

Indexed keywords

ABAMECTIN; AMPHOTERICIN B; CYCLOSPORIN; EPOTHILONE A; EPOTHILONE B; EPOTHILONE D; ERYTHROMYCIN; LAULIMALIDE; MACROCYCLIC COMPOUND; PELORUSIDE; RIFAMPICIN; SANSALVAMIDE A; TEMSIROLIMUS; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BIOINFORMATICS; CHEMICAL ANALYSIS; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; ANTICARCINOGENIC AGENTS; MACROCYCLIC COMPOUNDS; MOLECULAR CONFORMATION; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77955615249     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610792232060     Document Type: Article

References (178)

1. McNaught, A. D.; Wilkinson, A. IUPAC. Compendium of Chemical Terminology; Blackwell Science Publications, 1997.
2. Hill, J. W.; Carothers, W. H. Studies of polymerization and ring formation. XIX.1 many-membered cyclic anhydrides. J. Am. Chem. Soc., 1933, 55, 5023-5031.
3. Lindoy, L. F. The Chemistry of Macrocyclic Ligand Complexes; Cambridge University Press: Cambridge, 1989.
4. Driggers, E. M.; Hale, S. P.; Lee, J.; Terrett, N. K. The exploration of macrocycles for drug discovery - an underexploited structural class. Nat. Rev. Drug Discov., 2008, 7, 608-624.
5. Nuhn, P.; Wessjohann, L. A. Naturstoffchemie: Mikrobielle, pflanzliche und tierische Naturstoffe; Hirzel: Stuttgart, 2006.
6. Wessjohann, L. A.; Ruijter, E.; Garcia-Rivera, D.; Brandt, W. What can a chemist learn from nature's macrocycles? - A brief, conceptual view. Mol. Divers., 2005, 9, 171-186.
7. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. DrugDeliv. Rev., 1997, 23, 3-25.
8. Koehn, F. E.; Carter, G. T. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov., 2005, 4, 206-220.
9. Brandt, W.; Mrestani-Klaus, C.; Schinke, H.; Neubert, K.; Barth, A.; Schmidt, R.; Schiller, P. W.; Höltje, H. D. The mu opioid receptor binding pharmacophore conformation of ornithine containing cyclic beta-casomorphin analogues and related peptides. Quant. Struct.-Act. Relat., 1995, 14, 417-426.
10. Brandt, W.; Stoldt, M.; Schinke, H. The mu- and delta-opioid pharmacophore conformations of cyclic beta-casomorphin analogues indicate docking of the Phe(3) residue to different domains of the opioid receptors. J. Comput. Aided Mol. Des., 1996, 10, 201-212.
11. Brandt, W. Molecular-Modelling-Studien zur Aufklärung der Struktur-Wirkungsbeziehungen bei Opioiden und zu Mechanismen der molekularen Erkennung und der Enzymkatalyse an Dipeptidyl-Peptidase IV. Habilitation, Martin-Luther-University Halle-Wittenberg, 1996.
12. Schiller, P. W.; Schmidt, R.; Weltrowska, G.; Berezowska, I.; Nguyen, T. M. D.; Dupuis, S.; Chung, N. N.; Lemieux, C.; Wilkes, C.; Carpenter, K. A. Conformationally constrained opioid pepti-de analogs with novel activity profiles. Lett. Pept. Sci., 1998, 5, 209-214.
13. Schmidt, R.; Neubert, K.; Barth, A.; Liebmann, C; Schnittler, M.; Chung, N. N.; Schiller, P. W. Structure-activity-relationships of cyclic beta-casomorphin-5 analogs. Peptides, 1991, 12, 1175-1180.
14. Schmidt, R.; Neubert, K. Cyclization Studies with Tetrapeptide and Pentapeptide Sequences Corresponding to Beta-Casomorphins. Int. J. Pept. Prot. Res., 1991, 37, 502-507.
15. Schmidt, R.; Vogel, D.; Mrestani-Klaus, C.; Brandt, W.; Neubert, K.; Chung, N. N.; Lemieux, C.; Schiller, P. W. Cyclic beta-casomorphin analogs with mixed mu-agonist delta-antagonist properties - synthesis, pharmacological characterization, and conforma-tional aspects. J. Med. Chem., 1994, 37, 1136-1144.
16. Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem., 2002, 45, 2615-2623.
17. Bornscheuer, U. T.; Altenbuchner, J.; Meyer, H. H. Directed evolution of an esterase for the stereoselective resolution of a key intermediate in the synthesis of epothilones. Biotechnol. Bioeng., 1998, 58, 554-559.
18. Mulzer, J.; Mantoulidis, A. Synthesis of the C(1)-C(9) segment of the cytotoxic macrolides epothilon A and B. Tetrahedron Lett. 1996, 37, 9179-9182.
19. Altmann, K. H.; Pfeiffer, B.; Arseniyadis, S.; Pratt, B. A.; Nico-laou, K. C. The chemistry and biology of epothilones - The wheel keeps turning. ChemMedChem 2007, 2, 396-423.
20. Wessjohann, L. Epothilones: Promising natural products with taxol-like activity. Angew. Chem. Int. Ed., 1997, 36, 715-718.
21. Wessjohann, L. A.; Scheid, G. Synthetic Access to Epothilones-Natural Products with Extraordinary Anticancer Activity. In Organic Synthesis Highlights; Schmalz, H. G. Ed.; Wiley-VCH: Weinheim, 2000, pp. 251-267.
22. Ganesan, A. Natural products as a hunting ground for combinatorial chemistry. Curr. Opin. Biotechnol., 2004, 15, 584-590.
23. Wang, Y. L.; Xiao, J. W.; Suzek, T. O.; Zhang, J.; Wang, J. Y.; Bryant, S. H. PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res., 2009, 37, W623-W633.
24. Brown, F. K. Chemoinformatics: What is it and how does it impact drug discovery. Annu. Rep. Med. Chem., 1998, 33, 375-384.
25. Gasteiger, J. Handbook of Chemoinformatics; Wiley-VCH: Wein-heim, 2003.
26. Skaanderup, P. R.; Jensent, T. Synthesis of the macrocyclic core of (-)-pladienolide B. Org. Lett., 2008, 10, 2821-2824.
27. Fergus, S.; Bender, A.; Spring, D. R. Assessment of structural diversity in combinatorial synthesis. Curr. Opin. Chem. Biol., 2005, 9, 304-309.
28. Wityak, J.; Fevig, J. M.; Jackson, S. A.; Johnson, A. L.; Mousa, S. A.; Parthasarathy, A.; Wells, G. J.; Degrado, W. F.; Wexler, R. R. Synthesis and antiplatelet activity of dmp-757 analogs. Bioorg. Med. Chem. Lett., 1995, 5, 2097-2100.
29. Kim, T. K.; Hewavitharana, A. K.; Shaw, P. N.; Fuerst, J. A. Discovery of a new source of rifamycin antibiotics in marine sponge actinobacteria by phylogenetic prediction. Appl. Environ. Micro-biol., 2006, 72, 2118-2125.
30. Wessjohann, L. A.; Rhoden, C. R. B.; Rivera, D. G.; Vercillo, O. E. Cyclic peptidomimetics and pseudopeptides from multicomponent reactions. Top. Heterocycl. Chem. 2010, 23, 199-226.
31. Wessjohann, L. A.; Rivera, D. G.; Vercillo, O. E. Multiple mul-ticomponent macrocyclizations (MiBs): a strategic development toward macrocycle diversity. Chem. Rev., 2009, 109, 796-814.
32. Scheid, G.; Ruijter, E.; Konarzycka-Bessler, M.; Bornscheuer, U. T.; Wessjohann, L. A. Synthesis and resolution of a key building block for epothilones: a comparison of asymmetric synthesis, chemical and enzymatic resolution. Tetrahedron Asymmetr. 2004, 15, 2861-2869.
33. Gharbi-Benarous, J.; Evrard-Todeschi, N.; Ladam, P.; Bertho, G.; Delaforge, M.; Girault, J. P. Conformational analysis of josamycin, a 16-membered macrolide free in solution and bound to bacterial ribosomes. J. Chem. Soc., Perkin Trans. 1999, 2, 529-543.
34. Scherer, K.; Abels, C.; Bäumler, W.; Ackermann, G.; Szeimies, R. M. Structure-activity relationships of three differently substituted 2,7,12,17-tetrakis-(beta-methoxyethyl) porphycene derivatives in vitro. Arch. Dermatol. Res., 2004, 295, 535-541.
35. Sedrani, R.; Kallen, J.; Cabrejas, L. M. M.; Papageorgiou, C. D.; Senia, F.; Rohrbach, S.; Wagner, D.; Thai, B.; Eme, A. M. J.; France, J.; Oberer, L.; Rihs, G.; Zenke, G.; Wagner, J. Sanglifehrin-cyclophilin interaction: Degradation work, synthetic macro-cyclic analogues, X-ray crystal structure, and binding data. J. Am. Chem. Soc., 2003, 125, 3849-3859.
36. Raboisson, P.; de Kock, H.; Rosenquist, A.; Nilsson, M.; Salvador-Oden, L.; Lin, T. I.; Roue, N.; Ivanov, V.; Wähling, H.; Wick-ström, K.; Hamelink, E.; Edlund, M.; Vrang, L.; Vendeville, S.; Van de Vreken, W.; McGowan, D.; Tahri, A.; Hu, L. L.; Boutton, C.; Lenz, O.; Delouvroy, F.; Pille, G.; Surleraux, D.; Wigerinck, P.; Samuelsson, B.; Simmen, K. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorg. Med. Chem. Lett., 2008, 18, 4853-4858.
37. Fürstner, A.; Kirk, D.; Fenster, M. B.; Aissa, C.; De Souza, D.; Nevado, C.; Tuttle, T.; Thiel, W.; Müller, O. Latrunculin analogues with improved biological profiles by diverted total synthesis: Preparation, evaluation, and computational analysis. Chem. Eur. J., 2007, 13, 135-149.
38. Estrada, E.; Perdomo-López, I.; Torres-Labandeira, J. J. Combination of 2D-, 3D-connectivity and quantum chemical descriptors in QSPR. Complexation of alpha- and,beta-cyclodextrin with benzene derivatives. J. Chem. Inf. Comput. Sci., 2001, 41, 1561-1568.
39. Katritzky, A. R.; Fara, D. C.; Yang, H. F.; Karelson, M.; Suzuki, T.; Solov'ev, V. P.; Varnek, A. Quantitative structure-property relationship modeling of beta-cyclodextrin complexation free energies. J. Chem. Inf. Comput. Sci., 2004, 44, 529-541.
40. Suzuki, T.; Ishida, M.; Fabian, W. M. F. Classical QSAR and comparative molecular field analyses of the host-guest interaction of organic molecules with cyclodextrins. J. Comput. Aided Mol. Des., 2000, 14, 669-678.
41. Kadish, K. M.; Shen, J.; Fremond, L.; Chen, P.; El Ojaimi, M.; Chkounda, M.; Gros, C. P.; Barbe, J. M.; Ohkubo, K.; Fukuzumi, S.; Guilard, R. Clarification of the oxidation state of cobalt corroles in heterogeneous and homogeneous catalytic reduction of dioxygen. Inorg. Chem., 2008, 47, 6726-6737.
42. Pérez-Garrido, A.; Helguera, A. M.; Guillén, A. A.; Cordeiro, M. N. D. S.; Escudero, A. G. Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins. Bioorg. Med. Chem., 2009, 17, 896-904.
43. Solov'ev, V. P.; Varnek, A. A. Structure-property modeling of metal binders using molecular fragments. Russ. Chem. Bull., 2004, 53, 1434-1445.
44. Fermeglia, M.; Ferrone, M.; Lodi, A.; Pricl, S. Host-guest inclusion complexes between anticancer drugs and [beta]-cyclodextrin: computational studies. Carbohydr. Polym., 2003, 53, 15-44.
45. Keseru, G. M.; Nogradi, M. Molecular similarity analysis on biologically active macrocyclic bis(bibenzyls). J. Mol. Recognit. 1996, 9, 133-138.
46. Klein, C. T.; Polheim, D.; Viernstein, H.; Wolschann, P. A method for predicting the free energies of complexation between beta-cyclodextrin and guest molecules. J. Inclusion Phenom. Macrocyc-lic Chem., 2000, 36, 409-423.
47. Klein, C. T.; Polheim, D.; Viernstein, H.; Wolschann, P. Predicting the free energies of complexation between cyclodextrins and guest molecules: Linear versus nonlinear models. Pharm. Res. 2000, 17, 358-365.
48. Owens, J.; Lipinski, C. Chris Lipinski discusses life and chemistry after the Rule of Five. Drug Discov. Today, 2003, 8, 12-16.
49. Newman, D. J.; Cragg, G. M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod., 2007, 70, 461-477.
50. Blondeau, J. M. The evolution and role of macrolides in infectious diseases. Expert Opin. Pharmacother., 2002, 3, 1131-1151.
51. Ōmura, S. Macrolide Antibiotics: Chemistry, Biology, and Practice; Academic Press: London, 2002.
52. Frank, A. T.; Farina, N. S.; Sawwan, N.; Wauchope, O. R.; Qi, M.; Brzostowska, E. M.; Chan, W.; Grasso, F. W.; Haberfield, P.; Greer, A. Natural macrocyclic molecules have a possible limited structural diversity. Mol. Divers., 2007, 11, 115-118.
53. Belofsky, G. N.; Jensen, P. R.; Fenical, W. Sansalvamide: A new cytotoxic cyclic depsipeptide produced by a marine fungus of the genus Fusarium. Tetrahedron Lett., 1999, 40, 2913-2916.
54. Cueto, M.; Jensen, P. R.; Fenical, W. N-Methylsansalvamide, a cytotoxic cyclic depsipeptide from a marine fungus of the genus Fusarium. Phytochemistry, 2000, 55, 223-226.
55. Hwang, Y.; Rowley, D.; Rhodes, D.; Gertsch, J.; Fenical, W.; Bushman, F. Mechanism of inhibition of a poxvirus topoisomerase by the marine natural product sansalvamide A. Mol. Pharmacol., 1999, 55, 1049-1053.
56. Pan, P. S.; McGuire, K. L.; McAlpine, S. R. Identification of Sansalvamide a analog potent against pancreatic cancer cell lines. Bioorg. Med. Chem. Lett., 2007, 17, 5072-5077.
57. Pan, P. S.; Vasko, R. C.; Lapera, S. A.; Johnson, V. A.; Sellers, R. P.; Lin, C. C.; Pan, C. M.; Davis, M. R.; Ardi, V. C.; McAlpine, S. R. A comprehensive study of Sansalvamide A derivatives: The structure-activity relationships of 78 derivatives in two pancreatic cancer cell lines. Bioorg. Med. Chem., 2009, 17, 5806-5825.
58. Artemenko, A. G.; Kovdienko, N. A.; Kuz'min, V. E.; Kamalov, G. L.; Lozitskaya, R. N.; Fedchuk, A. S.; Lozitsky, V. P.; Dyachenko, N. S.; Nosach, L. N. The analysis of structure-anticancer activity relationship in a set of macrocyclic pyridinophanes and their acyclic analogues on the basis of lattice model of molecule using fractal parameters. Exp. Oncol., 2002, 24, 123-127.
59. Kuz'min, V. E.; Lozitsky, V. P.; Kamalov, G. L.; Lozitskaya, R. N.; Zheltvay, A. I.; Fedtchouk, A. S.; Kryzhanovsky, D. N. Analysis of the structure-anticancer activity relationship in a set of Schiff bases of macrocyclic 2,6-bis(2-and 4-formylaryloxymethyl)pyridines. Acta Biochim. Pol., 2000, 47, 867-875.
60. Kuz'min, V. E.; Artemenko, A. G.; Lozitsky, V. P.; Muratov, E. N.; Fedtchouk, A. S.; Dyachenko, N. S.; Nosach, L. N.; Gridina, T. L.; Shitikova, L. I.; Mudrik, L. M.; Mescheriakov, A. K.; Chelom-bitko, V. A.; Zheltvay, A. I.; Vanden Eynde, J. J. The analysis of structure-anticancer and antiviral activity relationships for macro-cyclic pyridinophanes and their analogues on the basis of 4D QSAR models (simplex representation of molecular structure). Acta Biochim. Pol., 2002, 49, 157-168.
61. Kuz'min, V. E.; Artemenko, A. G.; Lozytska, R. N.; Fedtchouk, A. S.; Lozitsky, V. P.; Muratov, E. N.; Mescheriakov, A. K. Investigation of anticancer activity of macrocyclic Schiff bases by means of 4D-QSAR based on simplex representation of molecular structure. SAR QSAR Environ. Res., 2005, 16, 219-230.
62. Bollag, D. M.; Mcqueney, P. A.; Zhu, J.; Hensens, O.; Koupal, L.; Liesch, J.; Goetz, M.; Lazarides, E.; Woods, C. M. Epothilones, A new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res., 1995, 55, 2325-2333.
63. Heinz, D. W.; Schubert, W. D.; Höfle, G. Much anticipated - The bioactive conformation of epothilone and its binding to tubulin. Angew. Chem. Int. Ed, 2005, 44, 1298-1301.
64. Gerth, K.; Bedorf, N.; Höfle, G.; Irschik, H.; Reichenbach, H. Epothilons A and B: Antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria) - Production, physico-chemical and biological properties. J. Antibiot., 1996, 49, 560-563.
65. Höfle, G. H.; Bedorf, N.; Steinmetz, H.; Schomburg, D.; Gerth, K.; Reichenbach, H. Epothilone A and B - Novel 16-membered mac-rolides with cytotoxic activity: Isolation, crystal structure, and conformation in solution. Angew. Chem. Int. Ed, 1996, 35, 1567-1569.
66. Nicolaou, K. C.; Roschangar, F.; Vourloumis, D. Chemical biology of epothilones. Angew. Chem. Int. Ed. 1998, 37, 2015-2045.
67. Nicolaou, K. C.; Sarabia, F.; Ninkovic, S.; Finlay, M. R. V.; Boddy, C. N. C. Probing the ring size of epothilones: Total synthesis of [14]-, [15]-, [17]-, and [18]epothilones A. Angew. Chem. Int. Ed, 1998, 37, 81-84.
68. Mulzer, J.; Mantoulidis, A.; Öhler, E. Total syntheses of epothilones B and D. J. Org. Chem., 2000, 65, 7456-7467.
69. Wessjohann, L. A. Synthesis of natural-product-based compound libraries. Curr. Opin. Chem. Biol., 2000, 4, 303-309.
70. Altmann, K. H. The merger of natural product synthesis and medicinal chemistry: on the chemistry and chemical biology of epothilones. Org. Biomol. Chem., 2004, 2, 2137-2152.
71. Altmann, K. H.; Flörsheimer, A.; Bold, G.; Caravatti, G.; Wart-mann, M. Natural product-based drug discovery - Epothilones as lead structures for the discovery of new anticancer agents. Chimia, 2004, 58, 686-690.
72. Wessjohann, L. A.; Ruijter, E. Strategies for total and diversity- oriented synthesis of natural product(-like) macrocycles. Top. Curr. Chem., 2005; 137-184.
73. Lee, K. W.; Briggs, J. M. Comparative molecular field analysis (CoMFA) study of epothilones-tubulin depolymerization inhibitors: Pharmacophore development using 3D QSAR methods. J. Comput. Aided Mol. Des., 2001, 15, 41-55.
74. Nicolaou, K. C.; Vourloumis, D.; Li, T. H.; Pastor, J.; Winssinger, N.; He, Y.; Ninkovic, S.; Sarabia, F.; Vallberg, H.; Roschangar, F.; King, N. P.; Finlay, M. R. V.; Giannakakou, P.; VerdierPinard, P.; Hamel, E. Designed epothilones: Combinatorial synthesis, tubulin assembly properties, and cytotoxic action against taxol-resistant tumor cells. Angew. Chem. Int. Ed, 1997, 36, 2097-2103.
75. Ojima, I.; Chakravarty, S.; Inoue, T.; Lin, S. N.; He, L. F.; Horwitz, S. B.; Kuduk, S. D.; Danishefsky, S. J. A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc. Natl. Acad. Sci. USA, 1999, 96, 4256-4261.
76. Altmann, K. H.; Cachoux, F.; Caravatti, G.; Isarno, T.; Wartmann, M. Recent developments in the chemistry and biology of epothilones. Arkivoc, 2006, 131-141.
77. Yuan, W.; Luan, L. B.; Li, Y. N. CoMFA 3D-QSAR analysis of epothilones based on docking conformation and alignment. Chinese J. Chem., 2007, 25, 453-460.
78. Mohanraj, S.; Doble, M. 3-d QSAR studies of microtubule stabilizing antimitotic agents towards six cancer cell lines. QSAR Comb. Sci., 2006, 25, 952-960.
79. Pineda, O.; Farras, J.; Maccari, L.; Manetti, F.; Botta, M.; Vilar-rasa, J. Computational comparison of microtubule-stabilising agents laulimalide and peloruside with taxol and colchicine. Bioorg. Med. Chem. Lett., 2004, 14, 4825-4829.
80. Morita, H.; Tomizawa, Y.; Tsuchiya, T.; Hirasawa, Y.; Hashimoto, T.; Asakawa, Y. Antimitotic activity of two macrocyclic bis(bibenzyls), isoplagiochins A and B from the Liverwort Plagio- chila fruticosa. Bioorg. Med. Chem. Lett., 2009, 19, 493-496.
81. Hu, X.; Nguyen, K. T.; Verlinde, C. L. M. J.; Hol, W. G. J.; Pei, D. Structure-based design of a macrocyclic inhibitor for peptide de-formylase. J. Med. Chem., 2003, 46, 3771-3774.
82. Hu, X. B.; Nguyen, K. T.; Jiang, V. C.; Lofland, D.; Moser, H. E.; Pei, D. H. Macrocyclic inhibitors for peptide deformylase: A structure-activity relationship study of the ring size. J. Med. Chem., 2004, 47, 4941-4949.
83. Ōmura, S.; Morimoto, S.; Nagate, T.; Adachi, T.; Kohno, Y. Re-search-and-development of clarithromycin. Yakugaku Zasshi, 1992, 112, 593-614.
84. Kawashima, Y.; Yamada, Y.; Asaka, T.; Misawa, Y.; Kashimura, M.; Morimoto, S.; Ono, T.; Nagate, T.; Hatayama, K.; Hirono, S.; Moriguchi, I. Structure-activity relationship study of 6-O-methylerythromycin 9-O-substituted oxime derivatives. Chem. Pharm. Bull., 1994, 42, 1088-1095.
85. Hansch, C.; Fujita, T. Rho-sigma-Pi analysis method for correlation of biological activity + chemical structure. J. Am. Chem. Soc. 1964, 86, 1616-1626.
86. Honikel, K.; Sippel, A.; Hartmann, G. Mode of action of antibiotics on DNA-directed polymerase reactions. Hoppe-Seyler's Z. Physiol. Chem., 1968, 349, 957.
87. Sippel, A.; Hartmann, G. Mode of action of rifamycin on RNA polymerase reaction. Biochim. Biophys. Acta, 1968, 157, 218.
88. Lancini, G. C.; Sartori, G. Rifamycins 61 - in vivo inhibition of RNA synthesis by rifamycins. Experientia, 1968, 24, 1105.
89. Lancini, G. C.; Gallo, G. G.; Sartori, G.; Sensi, P. Isolation and structure of rifamycin l and its biogenetic relationship with other ri-famycins. J. Antibiot., 1969, 22, 369-&.
90. Dimov, D.; Nedyalkova, Z.; Haladjova, S.; Schüürmann, G.; Mekenyan, O. QSAR modeling of antimycobacterial activity and activity against other bacteria of 3-formyl rifamycin SV derivatives. Quant. Struct.-Act. Relat., 2001, 20, 298-318.
91. Frontali, L.; Tecce, G. In: Antibiotics; Gotlieb, D.; Shaw, P. D. Eds.; Springer-Verlag: Berlin, Heidelberg, New York, 1967; p 415.
92. Van Epps, H. L. Rene dubos: unearthing antibiotics. J. Exp. Med., 2006, 203, 259.
93. Spathelf, B. M.; Rautenbach, M. Anti-listerial activity and structure-activity relationships of the six major tyrocidines, cyclic de-capeptides from Bacillus aneurinolyticus. Bioorg. Med. Chem., 2009, 17, 5541-5548.
94. Robinson, J. A.; Shankaramma, S. C.; Jettera, P.; Kienzl, U.; Schwendener, R. A.; Vrijbloed, J. W.; Obrecht, D. Properties and structure-activity studies of cyclic beta-hairpin peptidomimetics based on the cationic antimicrobial peptide protegrin I. Bioorg. Med. Chem., 2005, 13, 2055-2064.
95. Frecer, V. QSAR analysis of antimicrobial and haemolytic effects of cyclic cationic antimicrobial peptides derived from protegrin-1. Bioorg. Med. Chem., 2006, 14, 6065-6074.
96. Joao, H. C.; De Vreese, K.; Pauwels, R.; De Clercq, E.; Henson, G. W.; Bridger, G. J. Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors. J. Med. Chem., 1995, 38, 3865-3873.
97. Bridger, G. J.; Skerlj, R. T.; Padmanabhan, S.; Martellucci, S. A.; Henson, G. W.; Abrams, M. J.; Joao, H. C.; Witvrouw, M.; DeVreese, K.; Pauwels, R.; DeClercq, E. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit human immunodeficiency virus replication 2. Effect of heteroaromatic linkers on the activity of bi-cyclams. J. Med. Chem., 1996, 39, 109-119.
98. Fernández, M.; Caballero, J. QSAR models for predicting the activity of non-peptide luteinizing hormone-releasing hormone (LHRH) antagonists derived from erythromycin A using quantum chemical properties. J. Mol. Model., 2007, 13, 465-476.
99. Filicori, M.; Flamigni, C. GNRH agonists and antagonists - current clinical status. Drugs, 1988, 35, 63-82.
100. Khiat, A.; Boulanger, Y. Identification of the motilide pharmacophores using quantitative structure activity relationships. J. Pept. Res., 1998, 52, 321-328.
101. McFarland, J. W.; Berger, C. M.; Froshauer, S. A.; Hayashi, S. F.; Hecker, S. J.; Jaynes, B. H.; Jefson, M. R.; Kamicker, B. J.; Lipinski, C. A.; Lundy, K. M.; Reese, C. P.; Vu, C. B. Quantitative structure-activity relationships among macrolide antibacterial agents: In vitro and in vivo potency against Pasteurella multocida. J. Med. Chem., 1997, 40, 1340-1346.
102. Ladam, P.; Gharbibenarous, J.; Delaforge, M.; Vancalsteren, M. R.; Jankowski, C. K.; Girault, J. P. Conformational change due to es-terification of hydroxy-groups in erythromycin-A and its major metabolite - analysis of these derivatives with different biological properties using NMR and molecular-dynamics (MD) data. Bioorg. Med. Chem., 1995, 3, 587-604.
103. Vogel, D.; Schmidt, R.; Hartung, K.; Demuth, H. U.; Chung, N. N.; Schiller, P. W. Cyclic morphiceptin analogs: Cyclization studies and opioid activities in vitro. Int. J. Pept. Protein Res., 1996, 48, 495-502.
104. Linnankoski, J.; Ranta, V. P.; Yliperttula, M.; Urtti, A. Passive oral drug absorption can be predicted more reliably by experimental than computational models - Fact or myth. Eur. J. Pharm. Sci., 2008, 34, 129-139.
105. Rezai, T.; Yu, B.; Millhauser, G. L.; Jacobson, M. P.; Lokey, R. S. Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers. J. Am. Chem. Soc., 2006, 128, 2510-2511.
106. Burton, P. S.; Conradi, R. A.; Ho, N. F. H.; Hilgers, A. R.; Bor-chardt, R. T. How structural features influence the biomembrane permeability of peptides. J. Pharm. Sci., 1996, 85, 1336-1340.
107. Rezai, T.; Bock, J. E.; Zhou, M. V.; Kalyanaraman, C.; Lokey, R. S.; Jacobson, M. P. Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: Successful in silico prediction of the relative permeabilities of cyclic peptides. J. Am. Chem. Soc., 2006, 128, 14073-14080.
108. Bemporad, D.; Essex, J. W.; Luttmann, C. Permeation of small molecules through a lipid bilayer: A computer simulation study. J. Phys. Chem. B, 2004, 108, 4875-4884.
109. Bemporad, D.; Luttmann, C.; Essex, J. W. Computer simulation of small molecule permeation across a lipid bilayer: Dependence on bilayer properties and solute volume, size, and cross-sectional area. Biophys. J., 2004, 87, 1-13.
110. Bemporad, D.; Luttmann, C.; Essex, J. W. Behaviour of small solutes and large drugs in a lipid bilayer from computer simulations. BBA-Biomembranes, 2005, 1778, 1-21.
111. Kalyanaraman, C.; Jacobson, M. P. An atomistic model of passive membrane permeability: application to a series of FDA approved drugs. J. Comput. Aided Mol. Des., 2007, 21, 675-679.
112. Kwon, Y. U.; Kodadek, T. Quantitative comparison of the relative cell permeability of cyclic and linear peptides. Chem. Biol., 2007, 14, 671-677.
113. Boguslavsky, V.; Hruby, V. J.; O'Brien, D. F.; Misicka, A.; Lipkowski, A. W. Effect of peptide conformation on membrane permeability. J. Pept. Res., 2003, 61, 287-297.
114. Gangwar, S.; Jois, S. D. S.; Siahaan, T. J.; VanderVelde, D. G.; Stella, V. J.; Borchardt, R. T. The effect of conformation on membrane permeability of an acyloxyalkoxy-linked cyclic prodrug of a model hexapeptide. Pharm. Res., 1996, 13, 1657-1662.
115. Gudmundsson, O. S.; Jois, S. D. S.; Vander Velde, D. G.; Siahaan, T. J.; Wang, B.; Borchardt, R. T. The effect of conformation on the membrane permeation of coumarinic acid- and phenylpropionic acid-based cyclic prodrugs of opioid peptides. J. Pept. Res., 1999, 53, 383-392.
116. Okumu, F. W.; Pauletti, G. M.; Vander Velde, D. G.; Siahaan, T. J.; Borchardt, R. T. Effect of restricted conformational flexibility on the permeation of model hexapeptides across Caco-2 cell mono-layers. Pharm. Res., 1997, 14, 169-175.
117. Borchardt, R. T. Optimizing oral absorption of peptides using pro- drug strategies. J. Controlled Release, 1999, 62, 231-238.
118. Adessi, C.; Soto, C. Converting a peptide into a drug: Strategies to improve stability and bioavailability. Curr. Med. Chem. 2002, 9, 963-978.
119. Katsara, M.; Tselios, T.; Deraos, S.; Deraos, G.; Matsoukas, M. T.; Lazoura, E.; Matsoukas, J.; Apostolopoulos, V. Round and round we go: Cyclic peptides in disease. Curr. Med. Chem., 2006, 13, 2221-2232.
120. Wessjohann, L. A.; Andrade, C. K. Z.; Vercillo, O. E.; Rivera, D. G. Macrocyclic Peptoids: N-Alkylated Cyclopeptides and Dep-sipeptides. In: Targets in Heterocyclic Systems: Chemistry and Properties; Attanasi, O. A.; Spinelli, D. Eds.; Italian Society of Chemistry: 2007; pp 24-53.
121. Ano, R.; Kimura, Y.; Shima, M.; Matsuno, R.; Ueno, T.; Aka-matsu, M. Relationships between structure and high-throughput screening permeability of peptide derivatives and related compounds with artificial membranes: application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem., 2004, 12, 257-264.
122. Winiwarter, S.; Ax, F.; Lennernas, H.; Hallberg, A.; Pettersson, C.; Karlen, A. Hydrogen bonding descriptors in the prediction of human in vivo intestinal permeability. J. Mol. Graphics Modell., 2003, 21, 273-287.
123. Acharya, C.; Seo, P. R.; Polli, J. E.; MacKerell, A. D. Computational model for predicting chemical substituent effects on passive drug permeability across parallel artificial membranes. Mol. Pharmaceutics, 2008, 5, 818-828.
124. Di Fenza, A.; Alagona, G.; Ghio, C.; Leonardi, R.; Giolitti, A.; Madami, A. Caco-2 cell permeability modelling: a neural network coupled genetic algorithm approach. J. Comput. Aided Mol. Des., 2007, 21, 207-221.
125. Baginski, M.; Gariboldi, P.; Bruni, P.; Borowski, E. Conforma-tional analysis of amphotericin B. Biophys. Chem., 1997, 65, 91100.
126. Baginski, M.; Sternal, K.; Czub, J.; Borowski, E. Molecular modelling of membrane activity of amphotericin B, a polyene macrolide antifungal antibiotic. Acta Biochim. Pol., 2005, 52, 655-658.
127. Baginski, M.; Czub, J.; Sternal, K. Interaction of amphotericin B and its selected derivatives with membranes: Molecular modeling studies. Chem. Rec., 2006, 6, 320-332.
128. Czub, J.; Borowski, E.; Baginski, M. Interactions of amphotericin B derivatives with lipid membranes - A molecular dynamics study. BBA-Biomembranes, 2007, 1768, 2616-2626.
129. Mihailescu, D.; Smith, J. C. Atomic detail peptide-membrane interactions: Molecular dynamics simulation of gramicidin S in a DMPC bilayer. Biophys. J., 2000, 79, 1718-1730.
130. Prenner, E. J.; Lewis, R. N. A. H.; McElhaney, R. N. The interaction of the antimicrobial peptide Gramicidin S with lipid bilayer model and biological membranes. BBA-Biomembranes, 1999, 1462, 201-221.
131. Boldi, A. M. Libraries from natural product-like scaffolds. Curr. Opin. Chem. Biol., 2004, 8, 281-286.
132. Davidov, E. J.; Holland, J. M.; Marple, E. W.; Naylor, S. Advancing drug discovery through systems biology. Drug Discov. Today, 2003, 8, 175-183.
133. Hopkins, A. L.; Mason, J. S.; Overington, J. P. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol., 2006, 16, 127-136.
134. Lam, K. S. New aspects of natural products in drug discovery. Trends Microbiol., 2007, 15, 279-289.
135. Lipkowitz, K. B. Applications of computational chemistry to the study of cyclodextrins. Chem. Rev., 1998, 98, 1829-1873.
136. Malik, A.; Singh, H.; Andrabi, M.; Husain, S. A.; Ahmad, S. Databases and QSAR for Cancer Research. Cancer Inform., 2006, 2, 99-111.
137. Siegel, M. G.; Vieth, M. Drugs in other drugs: a new look at drugs as fragments. Drug Discov. Today, 2007, 12, 71-79.
138. Wase, N. V.; Wright, P. C. Systems biology of cyanobacterial secondary metabolite production and its role in drug discovery. Exp. Opin. Drug Discov., 2008, 3, 903-929.
139. Page, B.; Voigt, K. Recent history and development of environmental information systems and databases in Germany. Online Inform. Rev., 2003, 27, 37-50.
140. Christensen, S. B.; Franzyk, H.; Fralund, B.; Jaroszewski, J. W.; Stasrk, D.; Vedsø, P. Incorporation of the CrossFire Beilstein database into the organic chemistry curriculum at the Royal Danish School of Pharmacy. J. Chem. Educ., 2002, 79, 765-768.
141. Meehan, P.; Schofield, H. CrossFire: a structural revolution for chemists. Online Inform. Rev., 2001, 25, 241-249.
142. Cooke, F.; Schofield, H. A framework for the evaluation of chemical structure databases. J. Chem. Inf. Comput. Sci., 2001, 41, 1131-1140.
143. Parkar, F. A.; Parkin, D. Comparison of Beilstein CrossFirePlus- Reactions and the selective reaction databases under ISIS. J. Chem. Inf Comput. Sci. 1999, 39, 281-288.
144. Carino, S. E. Maximizing the usefulness of the data available in the Beilstein database with crossfire. Abstr. Papers Am. Chem. S, 1998, 215, U510.
145. Silhanek, J. Computer representation of chemical structures. Chem. Listy, 1997, 91, 237-250.
146. Donner, W. T. Economic aspects of chemical information. J. Chem. Inf. Comput. Sci., 1996, 36, 937-941.
147. Krieger, J. Beilstein launches new structure database. Chem. Eng. News, 1993, 71, 28-29.
148. Ji, Z. L.; Sun, L. Z.; Chen, X.; Zheng, C. J.; Yao, L. X.; Han, L. Y.; Cao, Z. W.; Wang, J. F.; Yeo, W. K.; Cai, C. Z.; Chen, Y. Z. Internet resources for proteins associated with drug therapeutic effects, adverse reactions and ADME. Drug Discov. Today, 2003, 8, 526-529.
149. Jónsdottir, S. Ó.; Jørgensen, F. S.; Brunak, S. Prediction methods and databases within chemoinformatics: emphasis on drugs and drug candidates. Bioinformatics, 2005, 21, 2145-2160.
150. Monge, A.; Arrault, A.; Marot, C.; Morin-Allory, L. Managing, profiling and analyzing a library of 2.6 million compounds gathered from 32 chemical providers. Mol. Divers., 2006, 10, 389-403.
151. Oprea, T. I.; Tropsha, A. Target, chemical and bioactivity databases - integration is key. Drug Discov. Today Technol., 2006, 3, 357-365.
152. Miller, M. A. Chemical database techniques in drug discovery. Nat. Rev. Drug Discov., 2002, 1, 220-227.
153. Goldberg, S. I.; Niemierko, A.; Turchin, A. Analysis of data errors in clinical research databases. AMIA Annu. Symp. Proc., 2008, 2008, 242-246.
154. Lambert, B. L.; Lin, S. J.; Chang, K. Y.; Gandhi, S. K. Similarity as a risk factor in drug-name confusion errors: the look-alike (Orthographic) and sound-alike (Phonetic) model. Med. Care, 1999, 37, 1214-1225.
155. Helma, C.; Kramer, S.; Pfahringer, B.; Gottmann, E. Data quality in predictive toxicology: Identification of chemical structures and calculation of chemical properties. Environ. Health Perspect., 2000, 108, 1029-1033.
156. Richard, A. M.; Gold, L. S.; Nicklaus, M. C. Chemical structure indexing of toxicity data on the Internet: Moving toward a flat world. Curr. Opin. Drug Discov. Devel., 2006, 9, 314-325.
157. Olah, M.; Mracec, M.; Ostopovici, L.; Rad, R.; Bora, A.; Hada-ruga, N.; Olah, I.; Banda, M.; Simon, Z.; Mracec, M. WOMBAT: world of molecular bioactivity. In Chemoinformatics in Drug Discovery; Oprea, T. I. Ed.; Wiley-VCH: Weinheim, 2004; pp 223-239.
158. Chemical errors found on WWW sites - A discussion of problems encountered while creating the ChemFinder WebServer database. http://chemfinder.com/errorsfound.asp [accessible via http://archive.org]
159. McNaught, A. D. The IUPAC international chemical identifier: InChl-A new standard for molecular informatics. Chem. Int., 2006, 28, 12-14.
160. Coles, S. J.; Day, N. E.; Murray-Rust, P.; Rzepa, H. S.; Zhang, Y. Enhancement of the chemical semantic web through the use of InChI identifiers. Org. Biomol. Chem., 2005, 3, 1832-1834.
161. Freemantle, M. Unique labels for compounds. Chem. Eng. News, 2002, 80, 33-35.
162. Weininger, D.; Weininger, A.; Weininger, J. L. Smiles. 2. Algorithm for generation of unique smiles notation. J. Chem. Inf. Com- put. Sci., 1989, 29, 97-101.
163. Prasanna, M. D.; Vondrasek, J.; Wlodawer, A.; Bhat, T. N. Application of InChI to curate, index, and query 3-D structures. Prot. Struct. Funct. Bioinf. 2005, 60, 1-4.
164. Heller, S. R.; McNaught, A. D. The IUPAC international chemical identifier (InChl). Chem. Int., 2009, 31, 7-9.
165. Nicolaou, K. C.; Boddy, C. N. C.; Bräse, S.; Winssinger, N. Chemistry, biology, and medicine of the glycopeptide antibiotics. Angew. Chem. Int. Ed., 1999, 38, 2097-2152.
166. Lindsley, C. W.; Chan, L. K.; Goess, B. C.; Joseph, R.; Shair, M. D. Solid-phase biomimetic synthesis of carpanone-like molecules. J. Am. Chem. Soc., 2000, 122, 422-423.
167. Stahl, P.; Kissau, L.; Mazitschek, R.; Huwe, A.; Furet, P.; Giannis, A.; Waldmann, H. Total synthesis and biological evaluation of the nakijiquinones. J. Am. Chem. Soc., 2001, 123, 11586-11593.
168. Stahl, P.; Kissau, L.; Mazitschek, R.; Giannis, A.; Waldmann, H. Natural product derived receptor tyrosine kinase inhibitors: identification of IGF1R, Tie-2, and VEGFR-3 inhibitors. Angew. Chem. Int. Ed, 2002, 41, 1174-1178.
169. Baumann, P.; Moran, N. A. Non-cultivable microorganisms from symbiotic associations of insects and other hosts. Antonie Van Leeuwenhoek, 1997, 72, 39-48.
170. Zeyaullah, M.; Kamli, M. R.; Islam, B.; Atif, M.; Benkhayal, F. A.; Nehal, M.; Rizvi, M. A.; Ali, A. Metagenomics-An advanced approach for non-cultivable micro-organisms. Biotechnol. Mol. Biol. Rev., 2009, 4, 49-54.
171. CTFile Formats. 2007. California, Symyx Technologies, Inc., 415 Oakmead ParkwaySunnyvale, CA 94085, http://www.symyx.com/solutions/white_papers/ctfile_formats.jsp
172. Liu, H.; Wang, J. A new way to enumerate cycles in graph. 57. 2006. Telecommunications, International Conference on Internet and Web Applications and Services. 2006.
173. Fernandez, M.; Caballero, J. QSAR models for predicting the activity of non-peptide luteinizing hormone-releasing hormone (LHRH) antagonists derived from erythromycin A using quantum chemical properties. J. Mol. Model., 2007, 13, 465-476.
174. Raman, P.; Cherezov, V.; Caffrey, M. The membrane protein data bank. Cell. Mol. Life Sci., 2006, 63, 36-51.
175. Kleywegt, G. J.; Jones, T. A. Databases in protein crystallography. Acta Crystallogr. D, 1998, 54, 1119-1131.
176. Goto, S.; Nishioka, T.; Kanehisa, M. LIGAND: chemical database for enzyme reactions. Bioinformatics, 1998, 14, 591-599.
177. Kanehisa, M.; Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res., 2000, 28, 27-30.
178. Chen, X.; Ji, Z. L.; Chen, Y. Z. TTD: Therapeutic target database. Nucleic Acids Res., 2002, 30, 412-415.